Spinal Muscular Atrophy Treatment and Outcomes

This webinar will provide an overview of U.S. Food and Drug Administration (FDA) approved therapies for SMA, the pros and cons of each therapy, physician's experiences with these therapies, and long-term issues regarding treatment and outcomes. Please note that the purpose of this webinar is strictly for information dissemination and discussion; APHL does not endorse any specific therapy or treatment. 

Audience: Individuals responsible for screening, diagnosing and treating SMA. 

Moderators: Amy Gaviglio, MS, LCGC, Co-Chair, APHL NewSTEPs New Disorders Workgroup 

George Dizikes, PhD, HCLD/CC (ABB), Co-Chair, APHL NewSTEPs New Disorders Workgroup

Speakers: 

Jennifer M. Kwon, MD, CGC, Faculty, University of Wisconsin School of Medicine and Public Health

Russell Butterfield, MD, PhD, Department of Neurology and Pediactrics, University of Utah

Melissa A. Gibbons, MS, CGC, Genetic Councelor, Children's Hospital Colorado

Julie Parsons, MD, Co-Director, Neuromuscular Clinic, Children's Hospital Colorado